Literature DB >> 16470128

The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.

Eugènia Negredo1, Bonaventura Clotet, Jordi Puig, Núria Pérez-Alvarez, Lidia Ruiz, Joan Romeu, José Moltó, Celestino Rey-Joly, Julià Blanco.   

Abstract

We conducted a pilot study to assess the effect of atorvastatin on HIV replication. Patients with stable HAART-controlled infection interrupted therapy and were randomly assigned to a control group or to start atorvastatin 40 or 80 mg/day. Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16470128     DOI： 10.1097/01.aids.0000210617.90954.0e

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  10 in total

1.  The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system.

Authors:  Scott L Letendre; Jennifer Marquie-Beck; Ronald J Ellis; Steven Paul Woods; Brookie Best; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Terry J Alexander; Janis Durelle; Robert Heaton; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-03       Impact factor: 4.147

2.  Statins as anti-inflammatory therapy in HIV disease?

Authors:  Andrew Carr
Journal:  J Infect Dis       Date:  2011-01-25       Impact factor: 5.226

3.  Sterol regulatory element-binding protein 2 couples HIV-1 transcription to cholesterol homeostasis and T cell activation.

Authors:  Harry E Taylor; Michael E Linde; Atanu K Khatua; Waldemar Popik; James E K Hildreth
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

Review 4.  The role of statins in the setting of HIV infection.

Authors:  Allison Ross Eckard; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

5.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

6.  Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.

Authors:  J C Probasco; S S Spudich; J Critchfield; E Lee; N Lollo; S G Deeks; R W Price
Journal:  Neurology       Date:  2008-08-12       Impact factor: 9.910

7.  Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.

Authors:  Richard D Moore; John G Bartlett; Joel E Gallant
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240

8.  A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.

Authors:  Eugènia Negredo; Montse Jiménez; Jordi Puig; Cora Loste; Núria Pérez-Álvarez; Victor Urrea; Patricia Echeverría; Anna Bonjoch; Bonaventura Clotet; Julià Blanco
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

Review 9.  Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.

Authors:  Kathleen V Fitch; Evelynne S Fulda; Steven K Grinspoon
Journal:  Curr Opin HIV AIDS       Date:  2022-07-16       Impact factor: 4.061

10.  Statins disrupt CCR5 and RANTES expression levels in CD4(+) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1.

Authors:  Alexey A Nabatov; Georgios Pollakis; Thomas Linnemann; William A Paxton; Michel P de Baar
Journal:  PLoS One       Date:  2007-05-23       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.